Basal Cell Carcinoma Market, by Treatment Type (Surgical (Surgical Excision, Electrodessication & Cutterage ED&C, Moh's Surgery, and Cryosurgery), Drugs (Topical Treatment, Advanced Medication, and Other), and Others (Radiation Therapy, Photodynamic Thera

Basal Cell Carcinoma Market, by Treatment Type (Surgical (Surgical Excision, Electrodessication & Cutterage ED&C, Moh's Surgery, and Cryosurgery), Drugs (Topical Treatment, Advanced Medication, and Other), and Others (Radiation Therapy, Photodynamic Therapy PDT, and Laser Therapy), by End User (Hospitals, Specialty Clinics, and Others), and by Region (North America, Latin America, Europe, Asia-Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Basal cell carcinoma is a type of skin cancer. Basal cell carcinoma begins in the basal cells a type of cell within the skin that produces new skin cells as old ones die off. Basal cell carcinoma often appears as a slightly transparent bump on the skin, though it can take other forms. Basal cell carcinoma occurs most often on areas of the skin that are exposed to the sun, such as head and neck. It is more common among fair-skinned people with sun exposure and is very rare among dark-skinned people.
Market Dynamics
Key players operating in the global basal cell carcinoma market are focusing on adoption of growth strategies such as product launch, regulatory approval, and research and development for the treatment of basal cell carcinoma, which is expected to drive the market growth during the forecast period. For instance, in January 2021, Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, announced dose administration for the first patient in a phase 2a clinical study of the company's lead drug candidate, STP705, for the treatment of cutaneous basal cell carcinoma. Moreover, in November 18 2021, Verrica Pharmaceuticals Inc., a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, announced that the U.S. Food and Drug Administration had accepted the company’s investigational new drug application for LTX-315, a potential first-in-class oncolytic peptide, for the treatment of basal cell carcinoma. The company expects to initiate its phase II trial of LTX-315 in basal cell carcinoma in the first quarter of 2022.
Key features of the study:
This report provides in-depth analysis of the global basal cell carcinoma market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global basal cell carcinoma market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Merck & Co., Inc., Sun Pharmaceutical Industries Ltd., Novartis AG., Bausch & Lomb Incorporated., Allergan, Perrigo Company plc, Taro Pharmaceutical Industries Ltd., Provectus Biopharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, Sanofi, and Mylan N.V.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global basal cell carcinoma market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global basal cell carcinoma market
Detailed Segmentation:
Global Basal Cell Carcinoma Market, By Treatment Type :
Surgical
Surgical Excision
Electrodessication & Cutterage ED&C
Moh's Surgery
Cryosurgery
Drugs
Topical Treatment
Advanced Medication
Other
Others
Radiation Therapy
Photodynamic Therapy PDT
Laser Therapy
Global Basal Cell Carcinoma Market, By End User :
Hospitals
Specialty Clinics
Others
Global Basal Cell Carcinoma Market, By Region:
North America
By Treatment Type
Surgical
Surgical Excision
Electrodessication & Cutterage ED&C
Moh's Surgery
Cryosurgery
Drugs
Topical Treatment
Advanced Medication
Other
Others
Radiation Therapy
Photodynamic Therapy PDT
Laser Therapy
By End User
Hospitals
Specialty Clinics
Others
By Country
U.S.
Canada
Latin America
By Treatment Type
Surgical
Surgical Excision
Electrodessication & Cutterage ED&C
Moh's Surgery
Cryosurgery
Drugs
Topical Treatment
Advanced Medication
Other
Others
Radiation Therapy
Photodynamic Therapy PDT
Laser Therapy
By End User
Hospitals
Specialty Clinics
Others
By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Treatment Type
Surgical
Surgical Excision
Electrodessication & Cutterage ED&C
Moh's Surgery
Cryosurgery
Drugs
Topical Treatment
Advanced Medication
Other
Others
Radiation Therapy
Photodynamic Therapy PDT
Laser Therapy
By End User
Hospitals
Specialty Clinics
Others
By Country
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Treatment Type
Surgical
Surgical Excision
Electrodessication & Cutterage ED&C
Moh's Surgery
Cryosurgery
Drugs
Topical Treatment
Advanced Medication
Other
Others
Radiation Therapy
Photodynamic Therapy PDT
Laser Therapy
By End User
Hospitals
Specialty Clinics
Others
By Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Treatment Type
Surgical
Surgical Excision
Electrodessication & Cutterage ED&C
Moh's Surgery
Cryosurgery
Drugs
Topical Treatment
Advanced Medication
Other
Others
Radiation Therapy
Photodynamic Therapy PDT
Laser Therapy
By End User
Hospitals
Specialty Clinics
Others
By Country
GCC
Israel
Rest of Middle East
Africa
By Treatment Type
Surgical
Surgical Excision
Electrodessication & Cutterage ED&C
Moh's Surgery
Cryosurgery
Drugs
Topical Treatment
Advanced Medication
Other
Others
Radiation Therapy
Photodynamic Therapy PDT
Laser Therapy
By End User
Hospitals
Specialty Clinics
Others
By Region/Country
South Africa
Central Africa
North Africa
Company Profiles
Merck & Co., Inc.,*
Company Highlights
Products Portfolio
Key Highlights
Financial Performance
Strategies
Sun Pharmaceutical Industries Ltd
Novartis AG
Bausch & Lomb Incorporated.
Allergan
Perrigo Company plc
Taro Pharmaceutical Industries Ltd
Provectus Biopharmaceuticals, Inc.
F. Hoffmann-La Roche Ltd
Sanofi
Mylan N.V.
“*” marked represents similar segmentation in other categories in the respective section.